MARKET

OPGN

OPGN

OpGen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.580
-0.070
-4.24%
Closed 16:00 11/26 EST
OPEN
1.560
PREV CLOSE
1.650
HIGH
1.600
LOW
1.540
VOLUME
427.04K
TURNOVER
--
52 WEEK HIGH
4.370
52 WEEK LOW
1.430
MARKET CAP
61.54M
P/E (TTM)
-1.3352
1D
5D
1M
3M
1Y
5Y
BRIEF-Opgen Posts Q3 Loss Per Share Of $0.16
reuters.com · 11/11 22:09
OpGen Q3 EPS $(0.16) Beats $(0.19) Estimate, Sales $1.24M Beat $1.22M Estimate
OpGen (NASDAQ:OPGN) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.19) by 15.79 percent. This is a 60 percent increase over losses of $(0.40) per share from the same
Benzinga · 11/11 21:25
OpGen EPS beats by $0.03, beats on revenue
OpGen (NASDAQ:OPGN): Q3 GAAP EPS of -$0.16 beats by $0.03. Revenue of $1.24M (+17.0% Y/Y) beats by $0.04M. Press Release
Seekingalpha · 11/11 21:10
-- Earnings Flash (OPGN) OPGEN Reports Q3 Revenue $1.2M, vs. Street Est of $1.2M
MT Newswires · 11/11 16:19
OpGen Q3 2021 Earnings Preview
OpGen (NASDAQ:OPGN) is scheduled to announce Q3 earnings results on Thursday, November 11th, after market close. The consensus EPS Estimate is -$0.19 (+52.5% Y/Y) and the consensus Revenue Estimate is
Seekingalpha · 11/10 22:35
Notable earnings after Thursday's close
ACHR, AEYE, AGRO, DADAAQN, ARRY, ASTR, AVGR, AVIR, BEEM, BLFS, BLNK, OTCPK:BOWFF, CODX, CPNG, OTCPK:EIFZF, FLO, GAN, GOVX, GP, HYFM, OTCQB:IGXT, INTZ, INUV, JAMF, JOBY, LAZR, LTRX, MAPS, OTC:NWHUF, ONTX,
Seekingalpha · 11/10 22:35
Earnings Outlook For OpGen
OpGen (NASDAQ: OPGN) is set to give its latest quarterly earnings report on Thursday, 2021-11-11. Here's what investors need to know before the announcement.
Benzinga · 11/10 15:59
OpGen, Inc. (OPGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 11/04 19:01
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OPGN. Analyze the recent business situations of OpGen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average OPGN stock price target is 4.175 with a high estimate of 4.350 and a low estimate of 4.000.
High4.350
Average4.175
Low4.000
Current 1.580
EPS
Actual
Estimate
-0.40-0.30-0.20-0.10
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 35
Institutional Holdings: 3.06M
% Owned: 7.87%
Shares Outstanding: 38.95M
TypeInstitutionsShares
Increased
13
397.53K
New
2
311.73K
Decreased
3
11.16K
Sold Out
7
106.81K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.30%
Pharmaceuticals & Medical Research
+0.44%
Key Executives
Non-Executive Chairman/Independent Director
William Rhodes
Chief Executive Officer/Director
Oliver Schacht
Chief Operating Officer
Johannes Bacher
Independent Director
Mario Crovetto
Independent Director
R. Donald Elsey
Independent Director
Prabhavathi Fernandes
No Data
About OPGN
OpGen, Inc. (OpGen) is a precision medicine company that uses molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information of products and services for global healthcare settings to guide clinicians with information about infections, improve patient outcomes and decrease the spread of infections caused by multidrug-resistant organisms (MDROs). The Company’s molecular diagnostics and informatics product candidates and services combine its Unyvero and Acuitas molecular diagnostics and Ares Genetics’ database and the Acuitas Lighthouse informatics platform.The molecular diagnostic tests provide microbial identification and antibiotic resistance gene information. The Acuitas Lighthouse informatics systems are cloud-based informatics offerings, which are designed to combine clinical lab test results with patient.

Webull offers kinds of OpGen Inc stock information, including NASDAQ:OPGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OPGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OPGN stock methods without spending real money on the virtual paper trading platform.